. 2022 Nov 24;28(12):2547–2554. doi: 10.1038/s41591-022-02075-9

Table 3.

Diagnostic accuracies of 4R-specific CSF MTBR-tau to distinguish CBD from FTLD-tau and control

Groups	n per group	Test	AUC	95% CI	P	Sensitivity (%)	Specificity (%)	Cutoff
CBD versus normal control	18 versus 29	CSF MTBR-tau₂₇₅/t-tau	0.810	0.672–0.949	0.0004	93.1	72.2	0.00582
CBD versus normal control	18 versus 29	CSF MTBR-tau₂₈₂/t-tau	0.889	0.790–0.988	<0.0001	89.7	77.9	0.01170
CBD versus FTLD-TDP	18 versus 21	CSF MTBR-tau₂₇₅/t-tau	0.701	0.530–0.872	0.0323	81.0	66.7	0.00559
CBD versus FTLD-TDP	18 versus 21	CSF MTBR-tau₂₈₂/t-tau	0.770	0.619–0.921	0.0041	81.0	72.2	0.01096
CBD versus other FTLD-tau (PSP, AGD, PiD)	18 versus 29	CSF MTBR-tau₂₇₅/t-tau	0.835	0.716–0.955	0.0001	89.7	66.7	0.00563
CBD versus other FTLD-tau (PSP, AGD, PiD)	18 versus 29	CSF MTBR-tau₂₈₂/t-tau	0.855	0.747–0.963	<0.0001	75.9	89.0	0.01219
CBD versus PiD	18 versus 5	CSF MTBR-tau₂₇₅/t-tau	0.800	0.572–1.000	0.0442	80.0	72.2	0.00599
CBD versus PiD	18 versus 5	CSF MTBR-tau₂₈₂/t-tau	0.806	0.543–1.000	0.0404	80.0	89.0	0.01219
CBD versus PSP	18 versus 22	CSF MTBR-tau₂₇₅/t-tau	0.828	0.696–0.960	0.0004	90.0	66.7	0.00563
CBD versus PSP	18 versus 22	CSF MTBR-tau₂₈₂/t-tau	0.854	0.736–0.972	0.0001	72.7	89.0	0.01220
CBD versus PSP (AD copathology removed)	15 versus 17	CSF MTBR-tau₂₇₅/t-tau	0.859	0.718–0.999	0.0005	82.4	86.7	0.00648
CBD versus PSP (AD copathology removed)	15 versus 17	CSF MTBR-tau₂₈₂/t-tau	0.886	0.763–1.000	0.0002	94.1	80.0	0.01164

CI, confidence interval.